Oppenheimer upgraded BioMarin (BMRN) to Outperform from Perform with a $98 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- Strong Growth Potential and Strategic Initiatives Drive BioMarin Pharmaceutical’s Outperform Rating
- BioMarin Pharmaceutical: Strong Q4 Performance, Future Growth Prospects, and Ongoing Challenges Justify Hold Rating
- BioMarin Pharmaceutical: Buy Rating Affirmed on Strong Growth Prospects and Strategic Developments
- BioMarin’s Earnings Call Highlights Strong Growth and Optimism
- BioMarin Pharmaceutical: Strong Growth Prospects with Strategic Initiatives Justifying Buy Rating